Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. currently faces 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units, showing a lack of examiner overlap in the current portfolio. HABTE, KAHSAY is the busiest examiner for the company, holding 1 busiest examiner pending action. With 2 pending office actions total, the workload is split between the identified busiest examiner and one other distinct examiner.
This distribution across 2 distinct art units suggests that the company's pharmaceutical innovations may span different specialized sub-fields. Since there are 2 distinct examiners involved, the prosecution team must adapt to different sets of examiner preferences and timelines. HABTE, KAHSAY, as the busiest examiner with 1 busiest examiner pending action, manages a portion of the active matters. This decentralized approach means that the outcome of one matter is unlikely to directly influence the other, as they are being handled by different individuals in different units. The Biotechnology & Pharmaceuticals portfolio requires separate strategies tailored to the 2 distinct examiners involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 84.9% | +7.5% |
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697015 | HALOGENATED PHENYLARSINE OXIDE COMPOUND AND APPLICATION THEREOF | HABTE, KAHSAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17995096 | APPLICATIONS OF P14K INHIBITOR IN INTRACELLULAR PROTEIN MISFOLDING-RELATED DISEASES AND LYSOSOMAL STORAGE DISEASES | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18697015 | HALOGENATED PHENYLARSINE OXIDE COMPOUND AND APPLICATION THEREOF | HABTE, KAHSAY | 1624 | §102§112DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 17995096 | APPLICATIONS OF P14K INHIBITOR IN INTRACELLULAR PROTEIN MISFOLDING-RELATED DISEASES AND LYSOSOMAL STORAGE DISEASES | CHONG, YONG SOO | 1623 | §112 | Final Rejection | — | Pending | Sep 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kahsay Habte has the most, with 1 of Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
